Zalicus Announces Closing of cHTS Service Business Sale to Horizon Discovery Group

Combination High Throughput Screening Platform and Related Assets Sold for $8 Million
Sale Increases Zalicus’ Cash Position and Percentage Ownership in the Proposed Merger with Epirus

CAMBRIDGE, Mass.  -- Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has closed the sale of its combination High Throughput Screening (cHTS) platform and related assets to Horizon Discovery Group for $8 million plus certain additional amounts relating to the working capital of these assets. As a result of the cHTS sales proceeds, the amount of Zalicus’ net cash expected at the closing of the merger with Epirus Biopharmaceutical will be in excess of $9 million.

Published: 12 June 2014
Written by Editor
Nasdaq   Up on News   Project Update  
Read more: Zalicus Inc ( ZLCS )

Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes in Post-Hoc Analysis

- Ability of receptor-targeted Lymphoseek to accurately target appropriate lymph nodes may lessen patient morbidity from extensive oral cavity surgery -

DUBLIN, Ohio-- Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced results from a post-hoc analysis of patient data from the Company’s Phase 3 clinical trial (NEO3-06) of Lymphoseek in head and neck cancer. 

Published: 11 June 2014
Written by Editor
AMEX   Project Updates   Up on News  
Read more: Navidea Biopharmaceuticals Inc ( NAVB )

Inovio Pharmaceuticals Initiates Immune Therapy Trial for Head & Neck Cancer Caused by HPV

Inovio Targets Most Rapidly Increasing Cancer in Men

BLUE BELL, Pa., June 10, 2014 -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. INO-3112 is a combination of Inovio's lead active immunotherapy product, VGX-3100, and its proprietary immune activator expressing interleukin-12 (IL-12). VGX-3100 is currently being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia (pre-cancer).

Published: 10 June 2014
Written by Editor
AMEX   Up on News   Project Update  
Read more: Inovio Pharmaceuticals Inc ( INO )

Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis

-- Study met primary efficacy endpoint with statistical significance after 24 weeks of treatment --
-- Safety data are supportive of differentiated product profile --
-- Investor conference call and webcast today at 5:00 p.m. EDT (2:00 p.m. PDT) --

SAN DIEGO, June 9, 2014  -- Receptos, Inc. (RCPT) today announced that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis (RMS) met the primary endpoint, reduction in MRI brain lesion activity. The overall safety profile of RPC1063 was consistent with the results of prior trials, and continues to support the differentiation of the drug candidate against other oral agents for treatment of RMS on the market or in clinical development.

Published: 10 June 2014
Written by Editor
Nasdaq   Up on News   Interesting News   Project Update  
Read more: Receptos Inc ( RCPT )

Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV

Initial cohort of HCV-infected patients begin dosing with ACH-3422 for seven days
Clinical trials may continue evaluating 200 mg of sovaprevir for HCV-infected patients
Timelines for reporting proof-of-concept results with ACH-3422, a proprietary uridine-analog nucleotide polymerase inhibitor, during the fall of 2014 and initiating all-oral combination studies by the end of 2014 remain on track

NEW HAVEN, Conn., June 10, 2014  -- Achillion Pharmaceuticals, Inc. (ACHN) today announced the Company has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for seven days in patients with genotype 1 chronic hepatitis C viral infection (HCV) in its ongoing Phase 1 clinical trial. Proof-of-concept results from this trial are expected to be reported during the fall of 2014. Furthermore, Achillion announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on sovaprevir, an NS3/4A protease inhibitor, to permit the conduct of trials in patients with HCV. Sovaprevir doses of 200 mg once daily, the previously evaluated dose that was well-tolerated with clinical activity in two completed Phase 2 studies, may be used in additional therapeutic clinical trials.

Published: 10 June 2014
Written by Editor
Nasdaq   FDA HC Decision   Up on News   Interesting News  
Read more: Achillion Pharmaceuticals Inc ( ACHN )
  1. Idenix Pharmaceuticals Inc ( IDIX )
  2. Halozyme Therapeutics Inc ( HALO )
  3. Advaxis Inc ( ADXS )
  4. Adherex Technologies Inc ( AHX )
  5. Can-Fite BioPharma Ltd ( CANF )